ctDNA for Early Detection of Recurrence in Melanoma - Trial NCT06246227
Access comprehensive clinical trial information for NCT06246227 through Pure Global AI's free database. This phase not specified trial is sponsored by Herlev and Gentofte Hospital and is currently Recruitment Completed. The study focuses on Melanoma. Target enrollment is 467 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Herlev and Gentofte Hospital
Timeline & Enrollment
N/A
Jul 01, 2019
Jan 01, 2028
Primary Outcome
Sensitivity of ctDNA for detection of metastatic disease,Specificity of ctDNA for detection of metastatic disease
Summary
This study examines circulating tumor DNA (ctDNA) as a biomarker for early detection of
 recurrence in high-risk patients, following treatment of primary melanoma. The hypothesis is
 that ctDNA can provide accurate detection of recurrence or metastasis, at the time of or
 earlier than current methods, leading to improved management and hopefully prognosis, based
 on earlier detection.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06246227
Non-Device Trial